|
1
|
Franko J, Feng W, Yip L, Genovese E and
Moser AJ: Non-functional neuroendocrine carcinoma of the pancreas:
Incidence, tumor biology, and outcomes in 2,158 patients. J
Gastrointest Surg. 14:541–548. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Batukbhai BDO and De Jesus-Acosta A: The
molecular and clinical landscape of pancreatic neuroendocrine
tumors. Pancreas. 48:9–21. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Batcher E, Madaj P and Gianoukakis AG:
Pancreatic neuroendocrine tumors. Endocr Res. 36:35–43. 2017.
View Article : Google Scholar
|
|
4
|
Stevenson M, Lines KE and Thakker RV:
Molecular genetic studies of pancreatic neuroendocrine tumors: New
therapeutic approaches. Endocrinol Metab Clin North Am. 47:525–548.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bauvois B: New facets of matrix
metalloproteinases MMP-2 and MMP-9 as cell surface transducers:
Outside-in signaling and relationship to tumor progression. Biochim
Biophys Acta. 1825:29–36. 2012.PubMed/NCBI
|
|
7
|
Shchors K, Nozawa H, Xu J, Rostker F,
Swigart-Brown L, Evan G and Hanahan D: Increased invasiveness of
MMP-9-deficient tumors in two mouse models of neuroendocrine
tumorigenesis. Oncogene. 32:502–513. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Krug S, Kühnemuth B, Griesmann H, Neesse
A, Mühlberg L, Boch M, Kortenhaus J, Fendrich V, Wiese D, Sipos B,
et al: CUX1: A modulator of tumour aggressiveness in pancreatic
neuroendocrine neoplasms. Endocr Relat Cancer. 21:879–890. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lawler J: The functions of
thrombospondin-1 and −2. Curr Opin Cell Biol. 12:634–640. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calabro NE, Kristofik NJ and Kyriakides
TR: Thrombospondin-2 and extracellular matrix assembly. Biochim
Biophys Acta. 1840:2396–2402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mir FA, Contreras-Ruiz L and Masli S:
Thrombospondin-1-dependent immune regulation by transforming growth
factor-β2-exposed antigen-presenting cells. Immunology.
146:547–556. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang Z, Strickland DK and Bornstein P:
Extracellular matrix metalloproteinase 2 levels are regulated by
the low density lipoprotein-related scavenger receptor and
thrombospondin 2. J Biol Chem. 276:8403–8408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lawler J and Detmar M: Tumor progression:
The effects of thrombospondin-1 and −2. Int J Biochem Cell Biol.
36:1038–1045. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koch M, Hussein F, Woeste A, Gründker C,
Frontzek K, Emons G and Hawighorst T: CD36-mediated activation of
endothelial cell apoptosis by an N-terminal recombinant fragment of
thrombospondin-2 inhibits breast cancer growth and metastasis in
vivo. Breast Cancer Res Treat. 128:337–346. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Farberov S and Meidan R: Functions and
transcriptional regulation of thrombospondins and their
interrelationship with fibroblast growth factor-2 in bovine luteal
cells. Biol Reprod. 91:582014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lopes N, Gregg D, Vasudevan S, Hassanain
H, Goldschmidt-Clermont P and Kovacic H: Thrombospondin 2 regulates
cell proliferation induced by Rac1 redox-dependent signaling. Mol
Cell Biol. 23:5401–5408. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Enenstein J, Gupta K, Vercellotti GM and
Hebbel RP: Thrombin-stimulated calcium mobilization is inhibited by
thrombospondin via CD36. Exp Cell Res. 238:465–471. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wilson BJ, Harada R, LeDuy L, Hollenberg
MD and Nepveu A: CUX1 transcription factor is a downstream effector
of the proteinase-activated receptor 2 (PAR2). J Biol Chem.
284:36–45. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou W, Li Y, Gou S, Xiong J, Wu H, Wang
C, Yan H and Liu T: MiR-744 increases tumorigenicity of pancreatic
cancer by activating Wnt/β-catenin pathway. Oncotarget.
6:37557–37569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fléjou JF: WHO Classification of digestive
tumors: The fourth edition. Ann Pathol. 31 (5 Suppl):S27–S31.
2011.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang YY and Feng HM: MEG3 suppresses
human pancreatic neuroendocrine tumor cells growth and metastasis
by down-regulation of Mir-183. Cell Physiol Biochem. 44:345–356.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sadanandam A, Wullschleger S, Lyssiotis
CA, Grötzinger C, Barbi S, Bersani S, Körner J, Wafy I, Mafficini
A, Lawlor RT, et al: A cross-species analysis in pancreatic
neuroendocrine tumors reveals molecular subtypes with distinctive
clinical, metastatic, developmental, and metabolic characteristics.
Cancer Discov. 5:1296–1313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park M, Kim M, Hwang D, Park M, Kim WK,
Kim SK, Shin J, Park ES, Kang CM, Paik YK and Kim H:
Characterization of gene expression and activated signaling
pathways in solid-pseudopapillary neoplasm of pancreas. Mod Pathol.
27:580–593. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nezu Y, Hagiwara K, Yamamoto Y, Fujiwara
T, Matsuo K, Yoshida A, Kawai A, Saito T and Ochiya T: miR-135b, a
key regulator of malignancy, is linked to poor prognosis in human
myxoid liposarcoma. Oncogene. 35:6177–6188. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen PC, Tang CH, Lin LW, Tsai CH, Chu CY,
Lin TH and Huang YL: Thrombospondin-2 promotes prostate cancer bone
metastasis by the up-regulation of matrix metalloproteinase-2
through down-regulating miR-376c expression. J Hematol Oncol.
10:332017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Slavin S, Yeh CR, Da J, Yu S, Miyamoto H,
Messing EM, Guancial E and Yeh S: Estrogen receptor alpha in
cancer-associated fibroblasts suppresses prostate cancer invasion
via modulation of thrombospondin 2 and matrix metalloproteinase 3.
Carcinogenesis. 35:1301–1309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ao R, Guan L, Wang Y and Wang JN:
Silencing of COL1A2, COL6A3, and THBS2 inhibits gastric cancer cell
proliferation, migration, and invasion while promoting apoptosis
through the PI3k-Akt signaling pathway. J Cell Biochem.
119:4420–4434. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meng H, Zhang X, Hankenson KD and Wang MM:
Thrombospondin 2 potentiates notch3/jagged1 signaling. J Biol Chem.
284:7866–7874. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou Q, Dong J, Luo R, Zhou X, Wang J and
Chen F: MicroRNA-20a regulates cell proliferation, apoptosis and
autophagy by targeting thrombospondin 2 in cervical cancer. Eur J
Pharmacol. 844:102–109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
MacLauchlan S, Yu J, Parrish M, Asoulin
TA, Schleicher M, Krady MM, Zeng J, Huang PL, Sessa WC and
Kyriakides TR: Endothelial nitric oxide synthase controls the
expression of the angiogenesis inhibitor thrombospondin 2. Proc
Natl Acad Sci USA. 108:E1137–E1145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
De Stefano D, Nicolaus G, Maiuri MC,
Cipolletta D, Galluzzi L, Cinelli MP, Tajana G, Iuvone T and
Carnuccio R: NF-kappaB blockade upregulates Bax, TSP-1, and TSP-2
expression in rat granulation tissue. J Mol Med (Berl). 87:481–492.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hatakeyama H, Nishizawa M, Nakagawa A,
Nakano S, Kigoshi T, Miyamori I and Uchida K: Thrombospondin
expression in aldosterone-producing adenomas. Hypertens Res.
25:523–527. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sha Z, Zhu X, Li N, Li Y and Li D:
Proto-oncogenic miR-744 is upregulated by transcription factor
c-Jun via a promoter activation mechanism. Oncotarget.
7:64977–64986. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sánchez-Jiménez C, Carrascoso I, Barrero J
and Izquierdo JM: Identification of a set of miRNAs differentially
expressed in transiently TIA-depleted HeLa cells by genome-wide
profiling. BMC Mol Biol. 14:42013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen S, Shi F, Zhang W, Zhou Y and Huang
J: miR-744-5p inhibits non-small cell lung cancer proliferation and
invasion by directly targeting PAX2. Technol Cancer Res Treat.
18:15330338198769132019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sui Y, Lin G, Zheng Y and Huang W: LncRNA
MAFG-AS1 boosts the proliferation of lung adenocarcinoma cells via
regulating miR-744-5p/MAFG axis. Eur J Pharmacol. 859:1724652019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kleemann M, Schneider H, Unger K, Sander
P, Schneider EM, Fischer-Posovszky P, Handrick R and Otte K:
MiR-744-5p inducing cell death by directly targeting HNRNPC and
NFIX in ovarian cancer cells. Sci Rep. 8:90202018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ching T, Song MA, Tiirikainen M, Molnar J,
Berry M, Towner D and Garmire L: Genome-wide hypermethylation
coupled with promoter hypomethylation in the chorioamniotic
membranes of early onset pre-eclampsia. Mol Hum Reprod. 20:885–904.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Miyamae M, Komatsu S, Ichikawa D,
Kawaguchi T, Hirajima S, Okajima W, Ohashi T, Imamura T, Konishi H,
Shiozaki A, et al: Plasma microRNA profiles: Identification of
miR-744 as a novel diagnostic and prognostic biomarker in
pancreatic cancer. Br J Cancer. 113:1467–1476. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang JC, Wu SC, Rau CS, Chen YC, Lu TH, Wu
YC, Tzeng SL, Wu CJ and Hsieh CH: TLR4/NF-κB-responsive microRNAs
and their potential target genes: A mouse model of skeletal muscle
ischemia-reperfusion injury. Biomed Res Int.
2015:4107212015.PubMed/NCBI
|
|
42
|
Ramdzan ZM and Nepveu A: CUX1: A
haploinsufficient tumour suppressor gene overexpressed in advanced
cancers. Nat Rev Cancer. 14:673–682. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hulea L and Nepveu A: CUX1 transcription
factors: From biochemical activities and cell-based assays to mouse
models and human diseases. Gene. 497:18–26. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Paul BM, Vassmer D, Taylor A, Magenheimer
L, Carlton CG, Piontek KB, Germino GG and Vanden Heuvel GB: Ectopic
expression of Cux1 is associated with reduced p27 expression and
increased apoptosis during late stage cyst progression upon
inactivation of Pkd1 in collecting ducts. Dev Dyn. 240:1493–1501.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Latreille R, Servant R, Darsigny M,
Marcoux S, Jones C, Perreault N and Boudreau F: Transcription
factor CUX1 is required for intestinal epithelial wound healing and
targets the VAV2-RAC1 signalling complex. Biochim Biophys Acta Mol
Cell Res. 1864:2347–2355. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen J, Zhou Z, Yao Y, Dai J, Zhou D, Wang
L and Zhang QQ: Dipalmitoylphosphatidic acid inhibits breast cancer
growth by suppressing angiogenesis via inhibition of the
CUX1/FGF1/HGF signalling pathway. J Cell Mol Med. 22:4760–4770.
2018. View Article : Google Scholar : PubMed/NCBI
|
